Gaylord Palms Convention Center
Florida Hall E
6000 West Osceola Parkway
Kissimmee, FL, 34746
12:00 – 12:30 PM EST: Lunch
12:30 – 12:40 PM EST: Welcome and Introduction
12:40 – 1:00 PM EST: Autologous Transplant, Novel Therapies, and the Current HL Paradigm
1:00 – 1:20 PM EST: A Practical Look at Integrating Novel Therapies in the Post-HCT Setting
1:20 – 1:30 PM EST: Key Takeaways and Audience Q&A
The effective management of patients with newly diagnosed advanced Hodgkin lymphoma (HL) has long centered on strategies such as risk-adapted chemotherapy and autologous stem cell transplantation (ASCT). While leading to good outcomes in many cases, new science is pointing to the potential for a closer integration of ASCT with many novel therapeutics already in use in patients with relapsed disease—including antibody-drug conjugates and checkpoint inhibitors, among others. The coming era in HL management will likely be defined by how these innovative treatments are utilized in conjunction with standard pillars of care in HL, particularly where data show that pre- and post-transplant outcomes in HL can be improved through state-of-the-art therapeutics. This lunch symposium will offer expert takes on the evidence that is driving this transition from a “monochrome” treatment landscape to one where novel therapeutics will play a greater role in the management of ASCT-eligible patients, both prior to and after transplant.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists, and BMT nurse specialists.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test and evaluation form.
Release and Expiration Date: Thursday, February 23, 2017
Time to Complete: 60 minutes
In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Anas Younes, MD
Chief, Lymphoma Service
Memorial Sloan Kettering Cancer Center
Professor, Weill-Cornell Medical College
New York, New York
Robert Chen, MD
Associate Professor of Medicine
Associate Director of Toni Stephenson Lymphoma Center
City of Hope Medical Center
PVI, PeerView Institute for Medical Education
The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Seattle Genetics.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.
Please visit our other symposia on AML, www.peerviewpress.com/AMLBMT, Fungal Infections, www.peerviewpress.com/infectionsHCT, Myelofibrosis, www.peerviewpress.com/MFBMT, and on Myeloma www.peerviewpress.com/MMBMT.